Outlook on the Diltiazem Global Market to 2028 - by Product Type, Application and Geography - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Diltiazem Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Capsules, Injection, and Tablets); Application (Angina, Hypertension, and Others), and Geography" report has been added to ResearchAndMarkets.com's offering.

The diltiazem market is projected to reach US$ 832.51 million by 2028 from US$ 369.95 million in 2021; it is expected to grow at a CAGR of 12.3% from 2021 to 2028.

The rising rate of coronavirus results in increased stress on the region's healthcare system, increasing the need for diagnostic tests in its healthcare system, encouraging the expansion of the sector in this region. As of 4 August 2021, the virus has affected over 51,859,200 people across the region and killed at least 1,137,425, as per Worldometer. Also, Italy, Spain, Germany, France, and the UK are the most affected European nations. As per the data given by Worldometer, till 4 August 2021, France, the UK, Spain, Italy, and Germany recorded 6,178,632; 5,923,820; 4,523,310; 4,363,374; and 3,782,326; respectively. COVID-19 cases and the death counts are also huge in these nations.

Hypertension has been recorded in various cases and retrospective groups as a possible risk factor for the frequency and severity of new SARS-CoV-2-associated disease (COVID-19). Since the SARS-CoV-2's high infectivity rates, a possible interaction between COVID-19 and hypertension is worrisome. Diltiazem may be helpful to treat hypertension associated with COVID-19. Further, diltiazem was proclaimed to alleviate acute lung injury by suppressing neutrophilic oxidative stress, which may relieve acute lung injury in COVID-19 patients. Overall, diltiazem plays dual effects on hypertension-linked COVID-19 treatment by lowering high blood pressure and restraining NF-kb signaling pathway-related inflammation.

The region witnessed some shortfall at the beginning of the COVID-19 crisis due to disruption in supply chain and demand due to lockdown announced by most European countries. Market players and end users lost their business due to the temporarily shutting down of industries in various regions. However, the diltiazem market witnessed growth during the pandemic as it is anticipated to inhibit viral growth and related hypertension. The global diltiazem market is segmented based on product type and application. Based on product type, in 2021, the tablets segment held the largest share of the market, by product. However, the capsules segment of Diltiazem market is also expected to witness fastest CAGR during 2021 to 2028. Moreover, based on application into angina, hypertension, and others. In 2021, the hypertension segment held the largest share of the market, by application. Whereas the Angina segment is expected to grow at the fastest CAGR of 12.9% during the coming years.

Reasons to buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Diltiazem Market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

• Increase in Cardiovascular Disease Incidence
• Increasing Elderly Population

Restraints

• Side Effects of Diltiazem

Opportunities

• Growth Opportunities in Developing Nations

Future Trends

• Recent Developments in Market

Companies Mentioned

• Bausch Health
• Teva Pharmaceutical Industries Ltd
• Mylan N.V
• Athenex
• Pfizer, Inc
• Glenmark
• Sandoz (Novartis Ag)
• Sun Pharmaceutical Company Ltd
• Hikma Pharmaceuticals
• Zydus Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/3nihi